English
简体中文
Total: £ 56.28
Published Date: 2024-12-04 | Pages: 124 | Tables: 225 | Pharma & Healthcare
The global market for Cell-based Flu Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cell-based Flu Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cell-based Flu Vaccine by region & country, by Type, and by Application.
The Cell-based Flu Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell-based Flu Vaccine.
Market Segmentation
By Company
GlaxoSmithKline
Sanofi
Pfizer
MedImmune, LLC
Intravacc
CSL Limited
E. Merck KG
Novartis
Danaher Corporation
SINOVAC
Segment by Type:
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
Aldults
Children
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cell-based Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cell-based Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cell-based Flu Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Cell-based Flu Vaccine Product Introduction
1.2 Global Cell-based Flu Vaccine Market Size Forecast
1.2.1 Global Cell-based Flu Vaccine Sales Value (2019-2030)
1.2.2 Global Cell-based Flu Vaccine Sales Volume (2019-2030)
1.2.3 Global Cell-based Flu Vaccine Sales Price (2019-2030)
1.3 Cell-based Flu Vaccine Market Trends & Drivers
1.3.1 Cell-based Flu Vaccine Industry Trends
1.3.2 Cell-based Flu Vaccine Market Drivers & Opportunity
1.3.3 Cell-based Flu Vaccine Market Challenges
1.3.4 Cell-based Flu Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cell-based Flu Vaccine Players Revenue Ranking (2023)
2.2 Global Cell-based Flu Vaccine Revenue by Company (2019-2024)
2.3 Global Cell-based Flu Vaccine Players Sales Volume Ranking (2023)
2.4 Global Cell-based Flu Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Cell-based Flu Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Cell-based Flu Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Cell-based Flu Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Cell-based Flu Vaccine
2.9 Cell-based Flu Vaccine Market Competitive Analysis
2.9.1 Cell-based Flu Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Cell-based Flu Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-based Flu Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Trivalent Influenza Vaccine
3.1.2 Quadrivalent Influenza Vaccine
3.2 Global Cell-based Flu Vaccine Sales Value by Type
3.2.1 Global Cell-based Flu Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cell-based Flu Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Cell-based Flu Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Cell-based Flu Vaccine Sales Volume by Type
3.3.1 Global Cell-based Flu Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Cell-based Flu Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Cell-based Flu Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Cell-based Flu Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Aldults
4.1.2 Children
4.2 Global Cell-based Flu Vaccine Sales Value by Application
4.2.1 Global Cell-based Flu Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cell-based Flu Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Cell-based Flu Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Cell-based Flu Vaccine Sales Volume by Application
4.3.1 Global Cell-based Flu Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Cell-based Flu Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Cell-based Flu Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Cell-based Flu Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Cell-based Flu Vaccine Sales Value by Region
5.1.1 Global Cell-based Flu Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cell-based Flu Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Cell-based Flu Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Cell-based Flu Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Cell-based Flu Vaccine Sales Volume by Region
5.2.1 Global Cell-based Flu Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Cell-based Flu Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Cell-based Flu Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Cell-based Flu Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Cell-based Flu Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Cell-based Flu Vaccine Sales Value, 2019-2030
5.4.2 North America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Cell-based Flu Vaccine Sales Value, 2019-2030
5.5.2 Europe Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Cell-based Flu Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Cell-based Flu Vaccine Sales Value, 2019-2030
5.7.2 South America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Cell-based Flu Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cell-based Flu Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cell-based Flu Vaccine Sales Value
6.2.1 Key Countries/Regions Cell-based Flu Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Cell-based Flu Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Cell-based Flu Vaccine Sales Value, 2019-2030
6.3.2 United States Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cell-based Flu Vaccine Sales Value, 2019-2030
6.4.2 Europe Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cell-based Flu Vaccine Sales Value, 2019-2030
6.5.2 China Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cell-based Flu Vaccine Sales Value, 2019-2030
6.6.2 Japan Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cell-based Flu Vaccine Sales Value, 2019-2030
6.7.2 South Korea Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cell-based Flu Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cell-based Flu Vaccine Sales Value, 2019-2030
6.9.2 India Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Information
7.1.2 GlaxoSmithKline Introduction and Business Overview
7.1.3 GlaxoSmithKline Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 GlaxoSmithKline Cell-based Flu Vaccine Product Offerings
7.1.5 GlaxoSmithKline Recent Development
7.2 Sanofi
7.2.1 Sanofi Company Information
7.2.2 Sanofi Introduction and Business Overview
7.2.3 Sanofi Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sanofi Cell-based Flu Vaccine Product Offerings
7.2.5 Sanofi Recent Development
7.3 Pfizer
7.3.1 Pfizer Company Information
7.3.2 Pfizer Introduction and Business Overview
7.3.3 Pfizer Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Pfizer Cell-based Flu Vaccine Product Offerings
7.3.5 Pfizer Recent Development
7.4 MedImmune, LLC
7.4.1 MedImmune, LLC Company Information
7.4.2 MedImmune, LLC Introduction and Business Overview
7.4.3 MedImmune, LLC Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 MedImmune, LLC Cell-based Flu Vaccine Product Offerings
7.4.5 MedImmune, LLC Recent Development
7.5 Intravacc
7.5.1 Intravacc Company Information
7.5.2 Intravacc Introduction and Business Overview
7.5.3 Intravacc Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Intravacc Cell-based Flu Vaccine Product Offerings
7.5.5 Intravacc Recent Development
7.6 CSL Limited
7.6.1 CSL Limited Company Information
7.6.2 CSL Limited Introduction and Business Overview
7.6.3 CSL Limited Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 CSL Limited Cell-based Flu Vaccine Product Offerings
7.6.5 CSL Limited Recent Development
7.7 E. Merck KG
7.7.1 E. Merck KG Company Information
7.7.2 E. Merck KG Introduction and Business Overview
7.7.3 E. Merck KG Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 E. Merck KG Cell-based Flu Vaccine Product Offerings
7.7.5 E. Merck KG Recent Development
7.8 Novartis
7.8.1 Novartis Company Information
7.8.2 Novartis Introduction and Business Overview
7.8.3 Novartis Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Novartis Cell-based Flu Vaccine Product Offerings
7.8.5 Novartis Recent Development
7.9 Danaher Corporation
7.9.1 Danaher Corporation Company Information
7.9.2 Danaher Corporation Introduction and Business Overview
7.9.3 Danaher Corporation Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Danaher Corporation Cell-based Flu Vaccine Product Offerings
7.9.5 Danaher Corporation Recent Development
7.10 SINOVAC
7.10.1 SINOVAC Company Information
7.10.2 SINOVAC Introduction and Business Overview
7.10.3 SINOVAC Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 SINOVAC Cell-based Flu Vaccine Product Offerings
7.10.5 SINOVAC Recent Development
8 Industry Chain Analysis
8.1 Cell-based Flu Vaccine Industrial Chain
8.2 Cell-based Flu Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cell-based Flu Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Cell-based Flu Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Cell-based Flu Vaccine Market Trends
Table 2. Cell-based Flu Vaccine Market Drivers & Opportunity
Table 3. Cell-based Flu Vaccine Market Challenges
Table 4. Cell-based Flu Vaccine Market Restraints
Table 5. Global Cell-based Flu Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Cell-based Flu Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Cell-based Flu Vaccine Sales Volume by Company (2019-2024) & (M Doses)
Table 8. Global Cell-based Flu Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Cell-based Flu Vaccine Price by Company (2019-2024) & (US$/Dose)
Table 10. Key Manufacturers Cell-based Flu Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Cell-based Flu Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Cell-based Flu Vaccine
Table 13. Global Cell-based Flu Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-based Flu Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Cell-based Flu Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Cell-based Flu Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Cell-based Flu Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Cell-based Flu Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Cell-based Flu Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Cell-based Flu Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (M Doses)
Table 22. Global Cell-based Flu Vaccine Sales Volume by Type (2019-2024) & (M Doses)
Table 23. Global Cell-based Flu Vaccine Sales Volume by Type (2025-2030) & (M Doses)
Table 24. Global Cell-based Flu Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Cell-based Flu Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Cell-based Flu Vaccine Price by Type (2019-2024) & (US$/Dose)
Table 27. Global Cell-based Flu Vaccine Price by Type (2025-2030) & (US$/Dose)
Table 28. Global Cell-based Flu Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Cell-based Flu Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Cell-based Flu Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Cell-based Flu Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Cell-based Flu Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Cell-based Flu Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (M Doses)
Table 34. Global Cell-based Flu Vaccine Sales Volume by Application (2019-2024) & (M Doses)
Table 35. Global Cell-based Flu Vaccine Sales Volume by Application (2025-2030) & (M Doses)
Table 36. Global Cell-based Flu Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Cell-based Flu Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Cell-based Flu Vaccine Price by Application (2019-2024) & (US$/Dose)
Table 39. Global Cell-based Flu Vaccine Price by Application (2025-2030) & (US$/Dose)
Table 40. Global Cell-based Flu Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Cell-based Flu Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Cell-based Flu Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Cell-based Flu Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Cell-based Flu Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Cell-based Flu Vaccine Sales Volume by Region (M Doses): 2019 VS 2023 VS 2030
Table 46. Global Cell-based Flu Vaccine Sales Volume by Region (2019-2024) & (M Doses)
Table 47. Global Cell-based Flu Vaccine Sales Volume by Region (2025-2030) & (M Doses)
Table 48. Global Cell-based Flu Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Cell-based Flu Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Cell-based Flu Vaccine Average Price by Region (2019-2024) & (US$/Dose)
Table 51. Global Cell-based Flu Vaccine Average Price by Region (2025-2030) & (US$/Dose)
Table 52. Key Countries/Regions Cell-based Flu Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Cell-based Flu Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Cell-based Flu Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Cell-based Flu Vaccine Sales Volume, (2019-2024) & (M Doses)
Table 56. Key Countries/Regions Cell-based Flu Vaccine Sales Volume, (2025-2030) & (M Doses)
Table 57. GlaxoSmithKline Company Information
Table 58. GlaxoSmithKline Introduction and Business Overview
Table 59. GlaxoSmithKline Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 60. GlaxoSmithKline Cell-based Flu Vaccine Product Offerings
Table 61. GlaxoSmithKline Recent Development
Table 62. Sanofi Company Information
Table 63. Sanofi Introduction and Business Overview
Table 64. Sanofi Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 65. Sanofi Cell-based Flu Vaccine Product Offerings
Table 66. Sanofi Recent Development
Table 67. Pfizer Company Information
Table 68. Pfizer Introduction and Business Overview
Table 69. Pfizer Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 70. Pfizer Cell-based Flu Vaccine Product Offerings
Table 71. Pfizer Recent Development
Table 72. MedImmune, LLC Company Information
Table 73. MedImmune, LLC Introduction and Business Overview
Table 74. MedImmune, LLC Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. MedImmune, LLC Cell-based Flu Vaccine Product Offerings
Table 76. MedImmune, LLC Recent Development
Table 77. Intravacc Company Information
Table 78. Intravacc Introduction and Business Overview
Table 79. Intravacc Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Intravacc Cell-based Flu Vaccine Product Offerings
Table 81. Intravacc Recent Development
Table 82. CSL Limited Company Information
Table 83. CSL Limited Introduction and Business Overview
Table 84. CSL Limited Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. CSL Limited Cell-based Flu Vaccine Product Offerings
Table 86. CSL Limited Recent Development
Table 87. E. Merck KG Company Information
Table 88. E. Merck KG Introduction and Business Overview
Table 89. E. Merck KG Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. E. Merck KG Cell-based Flu Vaccine Product Offerings
Table 91. E. Merck KG Recent Development
Table 92. Novartis Company Information
Table 93. Novartis Introduction and Business Overview
Table 94. Novartis Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Novartis Cell-based Flu Vaccine Product Offerings
Table 96. Novartis Recent Development
Table 97. Danaher Corporation Company Information
Table 98. Danaher Corporation Introduction and Business Overview
Table 99. Danaher Corporation Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. Danaher Corporation Cell-based Flu Vaccine Product Offerings
Table 101. Danaher Corporation Recent Development
Table 102. SINOVAC Company Information
Table 103. SINOVAC Introduction and Business Overview
Table 104. SINOVAC Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. SINOVAC Cell-based Flu Vaccine Product Offerings
Table 106. SINOVAC Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. Cell-based Flu Vaccine Downstream Customers
Table 110. Cell-based Flu Vaccine Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Cell-based Flu Vaccine Product Picture
Figure 2. Global Cell-based Flu Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Cell-based Flu Vaccine Sales Volume (2019-2030) & (M Doses)
Figure 5. Global Cell-based Flu Vaccine Sales Price (2019-2030) & (US$/Dose)
Figure 6. Cell-based Flu Vaccine Report Years Considered
Figure 7. Global Cell-based Flu Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Cell-based Flu Vaccine Players Sales Volume Ranking (2023) & (M Doses)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Cell-based Flu Vaccine Revenue in 2023
Figure 10. Cell-based Flu Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Trivalent Influenza Vaccine Picture
Figure 12. Quadrivalent Influenza Vaccine Picture
Figure 13. Global Cell-based Flu Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Cell-based Flu Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Cell-based Flu Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (M Doses)
Figure 16. Global Cell-based Flu Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Cell-based Flu Vaccine Price by Type (2019-2030) & (US$/Dose)
Figure 18. Product Picture of Aldults
Figure 19. Product Picture of Children
Figure 20. Global Cell-based Flu Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Cell-based Flu Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 22. Global Cell-based Flu Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (M Doses)
Figure 23. Global Cell-based Flu Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 24. Global Cell-based Flu Vaccine Price by Application (2019-2030) & (US$/Dose)
Figure 25. North America Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 27. Europe Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 29. Asia Pacific Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia Pacific Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 31. South America Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 32. South America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 35. Key Countries/Regions Cell-based Flu Vaccine Sales Value (%), (2019-2030)
Figure 36. Key Countries/Regions Cell-based Flu Vaccine Sales Volume (%), (2019-2030)
Figure 37. United States Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 38. United States Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 39. United States Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 40. Europe Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 41. Europe Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 42. Europe Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 43. China Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 44. China Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 45. China Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 46. Japan Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 47. Japan Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 48. Japan Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 49. South Korea Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 50. South Korea Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 51. South Korea Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 52. Southeast Asia Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 53. Southeast Asia Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 54. Southeast Asia Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 55. India Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 56. India Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 57. India Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 58. Cell-based Flu Vaccine Industrial Chain
Figure 59. Cell-based Flu Vaccine Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
